Active Biotech AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACTI.ST research report →
Companywww.activebiotech.com
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd.
- CEO
- Helen Tuvesson
- IPO
- 2003
- Employees
- 6
- HQ
- Lund, SE
Price Chart
Valuation
- Market Cap
- $89.99M
- P/E
- -5.36
- P/S
- 0.00
- P/B
- 3.94
- EV/EBITDA
- -1.09
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -117.83%
- ROIC
- -74.00%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-37,300,000 · 5.33%
- EPS
- $-0.03 · 70.44%
- Op Income
- $-37,600,000
- FCF YoY
- 100.00%
Performance & Tape
- 52W High
- $0.34
- 52W Low
- $0.04
- 50D MA
- $0.06
- 200D MA
- $0.08
- Beta
- 1.33
- Avg Volume
- 33.05M
Get TickerSpark's AI analysis on ACTI.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ACTI.ST Coverage
We haven't published any research on ACTI.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ACTI.ST Report →